Healing and relapse of severe peptic esophagitis after treatment with omeprazole - PubMed (original) (raw)
Clinical Trial
Healing and relapse of severe peptic esophagitis after treatment with omeprazole
D J Hetzel et al. Gastroenterology. 1988 Oct.
Abstract
We have studied the response of erosive or ulcerative esophagitis to treatment with omeprazole and its subsequent relapse on cessation of therapy in 196 patients. In the first phase of the study omeprazole (20 or 40 mg daily) was compared with placebo in 64 patients. After 4 wk there was endoscopic healing in 81% (25 of 31) of omeprazole-treated patients and in only 6% (2 of 32) of placebo-treated patients. Endoscopic healing of esophagitis was accompanied by symptom relief and histologic healing of ulceration. In the second (dose finding) phase a further 132 patients were randomized to omeprazole (20 or 40 mg daily) and endoscopic healing was assessed. In patients with the mildest grade of ulcerative esophagitis (grade 2), healing occurred at 4 wk in 87% receiving 20 mg and in 97% receiving 40 mg. In patients with grade 3 esophagitis, 67% (20 mg) and 88% (40 mg) were healed. Less than half the patients with grade 4 esophagitis (Barrett's ulcers or confluent ulceration) healed with either 20 mg (48%) or 40 mg (44%). Regression analysis in the 164 omeprazole-treated patients showed no evidence that healing was influenced by factors other than severity of esophagitis at entry and omeprazole dose. In phase 3 of the study the rate of endoscopic relapse was determined in 107 endoscopically healed patients after stopping omeprazole. Erosive or ulcerative esophagitis recurred in 88 of 107 (82%) by 6 mo. Neither initial dose, grade of esophagitis, nor smoking was shown to influence relapse rate. Omeprazole is a highly effective treatment for peptic esophagitis. The 40-mg/day dosage produces endoscopic healing slightly more quickly than the 20-mg/day dosage, and the initial endoscopic gradings are of prognostic value. Relapse occurs rapidly when treatment is stopped.
Similar articles
- Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study.
Sontag SJ, Robinson M, Roufail W, Hirschowitz BI, Sabesin SM, Wu WC, Behar J, Peterson WL, Kranz KR, Tarnawski A, Dayal Y, Berman R, Simon TJ. Sontag SJ, et al. Aliment Pharmacol Ther. 1997 Apr;11(2):373-80. doi: 10.1046/j.1365-2036.1997.141317000.x. Aliment Pharmacol Ther. 1997. PMID: 9146778 Clinical Trial. - Omeprazole in H2 receptor antagonist-resistant reflux esophagitis.
Marciano-D'Amore DA, Paterson WG, Da Costa LR, Beck IT. Marciano-D'Amore DA, et al. J Clin Gastroenterol. 1990 Dec;12(6):616-20. doi: 10.1097/00004836-199012000-00003. J Clin Gastroenterol. 1990. PMID: 1979984 - Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G; Italian Rabeprazole Study Group. Pace F, et al. Dig Liver Dis. 2005 Oct;37(10):741-50. doi: 10.1016/j.dld.2005.04.026. Dig Liver Dis. 2005. PMID: 16024305 Clinical Trial. - Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Chiba N. Chiba N. Can J Gastroenterol. 1997 Sep;11 Suppl B:66B-73B. Can J Gastroenterol. 1997. PMID: 9347181 Review. - Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
McTavish D, Buckley MM, Heel RC. McTavish D, et al. Drugs. 1991 Jul;42(1):138-70. doi: 10.2165/00003495-199142010-00008. Drugs. 1991. PMID: 1718683 Review.
Cited by
- Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion.
Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K, Toyota T, Shimosegawa T. Koike T, et al. Gut. 2001 Sep;49(3):330-4. doi: 10.1136/gut.49.3.330. Gut. 2001. PMID: 11511552 Free PMC article. - Does postoperative pH monitoring predict complicated gastroesophageal reflux in patients with esophageal atresia?
Koivusalo A, Pakarinen M, Rintala RJ, Lindahl H. Koivusalo A, et al. Pediatr Surg Int. 2004 Sep;20(9):670-4. doi: 10.1007/s00383-004-1270-z. Epub 2004 Sep 11. Pediatr Surg Int. 2004. PMID: 15372290 - Minimal changes in reflux esophagitis: red ones and white ones.
Hongo M. Hongo M. J Gastroenterol. 2006 Feb;41(2):95-9. doi: 10.1007/s00535-006-1775-4. J Gastroenterol. 2006. PMID: 16568367 Review. - Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease.
Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Zhang Q, et al. Gut. 2002 Jan;50(1):19-24. doi: 10.1136/gut.50.1.19. Gut. 2002. PMID: 11772961 Free PMC article. Clinical Trial. - Surgery for uncomplicated gastro-oesophageal reflux.
Watson A. Watson A. Gut. 1993 Mar;34(3):428-9. doi: 10.1136/gut.34.3.428. Gut. 1993. PMID: 8472995 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources